Table of Contents
Chemotherapy Research and Practice
Volume 2012 (2012), Article ID 648965, 7 pages
http://dx.doi.org/10.1155/2012/648965
Review Article

Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance

Departments of Pharmacology, Hematology and Medical Oncology, School of Medicine; Winship Cancer Institute; Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Suite 5001, 1510 Clifton Road, Atlanta, GA 30322, USA

Received 25 April 2012; Accepted 19 June 2012

Academic Editor: Sue S. Yom

Copyright © 2012 Rita Nahta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Carter, L. Presta, C. M. Gorman et al., “Humanization of an anti-p185(HER2) antibody for human cancer therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4285–4289, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire, “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar · View at Scopus
  3. J. Baselga, D. Tripathy, J. Mendelsohn et al., “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 737–744, 1996. View at Google Scholar · View at Scopus
  4. M. A. Cobleigh, C. L. Vogel, D. Tripathy et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2639–2648, 1999. View at Google Scholar · View at Scopus
  5. F. J. Esteva, V. Valero, D. Booser et al., “Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer,” Journal of Clinical Oncology, vol. 20, no. 7, pp. 1800–1808, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. D. Seidman, M. N. Fornier, F. J. Esteva et al., “Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification,” Journal of Clinical Oncology, vol. 19, no. 10, pp. 2587–2595, 2001. View at Google Scholar · View at Scopus
  7. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. C. L. Arteaga, M. X. Sliwkowski, C. K. Osborne, E. A. Perez, F. Puglisi, and L. Gianni, “Treatment of HER2-positive breast cancer: current status and future perspectives,” Nature Reviews Clinical Oncology, vol. 9, pp. 16–32, 2012. View at Google Scholar
  9. T. A. Bailey, H. Luan, R. J. Clubb, M. Naramura, V. Band, S. M. Raja et al., “Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance,” Journal of Carcinogenesis, vol. 10, article 28, 2011. View at Publisher · View at Google Scholar
  10. R. Nahta, “Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance,” Current Medicinal Chemistry, vol. 19, no. 7, pp. 1065–1075, 2012. View at Google Scholar
  11. R. Nahta, D. Yu, M. C. Hung, G. N. Hortobagyi, and F. J. Esteva, “Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer,” Nature Clinical Practice Oncology, vol. 3, no. 5, pp. 269–280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Y. Tsang and R. S. Finn, “HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies,” Drug Discovery Today: Therapeutic Strategies, vol. 106, pp. 6–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak, “Insulin-like growth factor-I receptor signaling and resistance to transtuzumab (Herceptin),” Journal of the National Cancer Institute, vol. 93, no. 24, pp. 1852–1857, 2001. View at Google Scholar · View at Scopus
  14. P. H. Tseng, Y. C. Wang, S. C. Weng et al., “Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor,” Molecular Pharmacology, vol. 70, no. 5, pp. 1534–1541, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Cornelissen, K. McLarty, V. Kersemans, and R. M. Reilly, “The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin),” Nuclear Medicine and Biology, vol. 35, no. 6, pp. 645–653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Jerome, N. Alami, S. Belanger et al., “Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo,” Cancer Research, vol. 66, no. 14, pp. 7245–7252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Oliveras-Ferraros, A. Vazquez-Martin, B. Martin-Castillo et al., “Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin),” International Journal of Oncology, vol. 37, no. 3, pp. 669–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Nahta and F. J. Esteva, “In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 2, pp. 186–190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Nahta, T. Takahashi, N. T. Ueno, M. C. Hung, and F. J. Esteva, “P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells,” Cancer Research, vol. 64, no. 11, pp. 3981–3986, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Nahta, L. X. H. Yuan, B. Zhang, R. Kobayashi, and F. J. Esteva, “Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells,” Cancer Research, vol. 65, pp. 11118–11128, 2005. View at Google Scholar
  21. X. Huang, L. Gao, S. Wang et al., “Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to herceptin,” Cancer Research, vol. 70, no. 3, pp. 1204–1214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. W. J. Köstler, G. Hudelist, W. Rabitsch et al., “Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 1, pp. 9–18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. B. L. Smith, D. Chin, W. Maltzman, K. Crosby, G. N. Hortobagyi, and S. S. Bacus, “The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins,” British Journal of Cancer, vol. 91, no. 6, pp. 1190–1194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Yerushalmi, K. A. Gelmon, S. Leung et al., “Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes,” Breast Cancer Research and Treatment, vol. 132, pp. 131–142, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. L. N. Harris, F. You, S. J. Schnitt et al., “Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer,” Clinical Cancer Research, vol. 13, no. 4, pp. 1198–1207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Gallardo, E. Lerma, D. Escuin, A. Tibau, J. Munoz, B. Ojeda et al., “Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas,” British Journal of Cancer, vol. 106, pp. 1367–1373, 2012. View at Publisher · View at Google Scholar
  27. H. Zhang and D. Yee, “Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer?” Clinical Cancer Research, vol. 12, no. 21, pp. 6323–6325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Berns, H. M. Horlings, B. T. Hennessy et al., “A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer,” Cancer Cell, vol. 12, no. 4, pp. 395–402, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. H. Lu, S. L. Wyszomierski, L. M. Tseng et al., “Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency,” Clinical Cancer Research, vol. 13, no. 19, pp. 5883–5888, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Nagata, K. H. Lan, X. Zhou et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients,” Cancer Cell, vol. 6, no. 2, pp. 117–127, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Ozbay, D. L. Durden, T. Liu, R. M. O'Regan, and R. Nahta, “In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 4, pp. 697–706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. F. J. Esteva, H. Guo, S. Zhang et al., “PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer,” American Journal of Pathology, vol. 177, no. 4, pp. 1647–1656, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Andre, M. Campone, R. O'Regan et al., “Phase I study of everolimus plus weekly paclitaxel and Trastuzumab in patients with metastatic breast cancer pretreated with Trastuzumab,” Journal of Clinical Oncology, vol. 28, no. 34, pp. 5110–5115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. S. S. Gayle, S. L. Arnold, R. M. O'Regan, and R. Nahta, “Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary Trastuzumab resistance,” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, pp. 151–162, 2012. View at Google Scholar
  35. P. K. Morrow, G. M. Wulf, J. Ensor, D. J. Booser, J. A. Moore, P. R. Flores et al., “Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy,” Journal of Clinical Oncology, vol. 29, pp. 3126–3132, 2011. View at Publisher · View at Google Scholar
  36. L. H. Wang, J. L. K. Chan, and W. Li, “Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells,” International Journal of Cancer, vol. 121, no. 1, pp. 157–164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Scaltriti, P. J. Eichhorn, J. Cortés et al., “Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3761–3766, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Shabaya and R. Nahta, “Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer,” in Breast Cancer—Current and Alternative Therapeutic Modalities, E. Gunduz and M. Gunduz, Eds., pp. 3–22, InTech, 2011. View at Google Scholar
  39. Y. Lu, X. Zi, and M. Pollak, “Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (herceptin) on SKBR3 breast cancer cells,” International Journal of Cancer, vol. 108, no. 3, pp. 334–341, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Lu, X. Zi, Y. Zhao, and M. Pollak, “Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 313, no. 3, pp. 709–715, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Dokmanovic, Y. Shen, T. M. Bonacci, D. S. Hirsch, and W. J. Wu, “Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance,” Molecular Cancer Therapeutics, vol. 10, no. 6, pp. 917–928, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. A. K. Chakraborty, K. Liang, and M. P. DiGiovanna, “Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer,” Cancer Research, vol. 68, no. 5, pp. 1538–1545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. B. C. Browne, J. Crown, N. Venkatesan et al., “Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells,” Annals of Oncology, vol. 22, no. 1, pp. 68–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Esparís-Ogando, A. Ocaña, R. Rodríguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella, “Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells,” Annals of Oncology, vol. 19, no. 11, pp. 1860–1869, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. D. L. Rowe, T. Ozbay, L. M. Bender, and R. Nahta, “Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer,” Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 1900–1908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Zavodovskaya, M. J. Campbell, B. A. Maddux et al., “Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells,” Journal of Cellular Biochemistry, vol. 103, no. 2, pp. 624–635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. W. D. Tap, G. Demetri, P. Barnette, J. Desai, P. Kavan, R. Tozer et al., “Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors,” Journal of Clinical Oncology, vol. 30, pp. 1849–1856, 2012. View at Publisher · View at Google Scholar
  48. A. Weickhardt, R. Doebele, A. Oton, J. Lettieri, D. Maxson, M. Reynolds et al., “A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 7, pp. 419–426, 2012. View at Publisher · View at Google Scholar
  49. L. Goetsch, A. Gonzalez, O. Leger et al., “A recombinant humanized anti-insulin-like growth factor-receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts,” International Journal of Cancer, vol. 113, no. 2, pp. 316–328, 2005. View at Publisher · View at Google Scholar · View at Scopus